PRMT5 and breast carcinoma: Lastly, we found that, compared to the single agent, co-treatment of TRAF6 and PRMT5 inhibitors significantly decreased cell viability in breast cancer cells (Figure 6J), which is in part achieved by enhancing cell apoptosis (Figure 6K).